Cabaletta Bio (NASDAQ:CABA) Receives "Overweight" Rating from Cantor Fitzgerald

Key Points

• Cantor Fitzgerald restated an “Overweight” rating on Cabaletta Bio with a $30 per-share price target, while consensus among analysts is mixed (six Buys, one Sell) and the average price target is $17 with an overall "Moderate Buy" rating.
• The stock trades around $2.94 with a market capitalization of about $327 million, a negative P/E and elevated volatility (beta 3.18); the company posted -$0.40 EPS last quarter (beating estimates) and analysts forecast roughly -1.5 EPS for the year.
• Cabaletta is a clinical-stage biotech developing CAAR‑T therapies, with its lead candidate DSG3‑CAART being evaluated for pemphigus vulgaris, a rare autoimmune blistering disease.

Cabaletta Bio (NASDAQ:CABA - Get Free Report)'s stock had its "overweight" rating restated by investment analysts at Cantor Fitzgerald in a report released on Monday,Benzinga reports. They presently have a $30.00 target price on the stock.

Several other analysts also recently issued reports on CABA. Morgan Stanley cut their target price on shares of Cabaletta Bio from $14.00 to $13.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 24th. Wall Street Zen downgraded shares of Cabaletta Bio from a "hold" rating to a "sell" rating in a research note on Saturday, April 18th. Guggenheim boosted their target price on shares of Cabaletta Bio from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, March 24th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Cabaletta Bio in a research note on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Cabaletta Bio has an average rating of "Moderate Buy" and an average price target of $17.00.

Cabaletta Bio Stock Performance

NASDAQ CABA opened at $2.94 on Monday. The stock has a market capitalization of $327.28 million, a P/E ratio of -1.29 and a beta of 3.18. Cabaletta Bio has a 1 year low of $1.11 and a 1 year high of $3.78. The business's fifty day moving average is $3.08 and its two-hundred day moving average is $2.70.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.05. On average, research analysts forecast that Cabaletta Bio will post -1.5 earnings per share for the current year.

Hedge Funds Weigh In On Cabaletta Bio

Institutional investors and hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new position in shares of Cabaletta Bio in the first quarter worth $32,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Cabaletta Bio in the fourth quarter worth $34,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Cabaletta Bio in the fourth quarter worth $38,000. Clear Harbor Asset Management LLC acquired a new position in shares of Cabaletta Bio in the fourth quarter worth $43,000. Finally, Jones Financial Companies Lllp acquired a new position in shares of Cabaletta Bio in the third quarter worth $47,000.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.